Business Context and Reporting Period
Company: Smith & Nephew plc
Reporting Period: Fiscal year ended December 31, 2013
Business Overview: A global medical technology business with leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine, and Trauma & Extremities. The Group operates in over 90 countries, organized into two primary divisions: Advanced Surgical Devices (ASD) and Advanced Wound Management (AWM).
Accounting Basis: International Financial Reporting Standards (IFRS).
Key Financial Metrics
| Metric | 2013 Value | 2012 Value | Change |
|---|---|---|---|
| Revenue | $4,351 million | $4,137 million | +5% (Reported) / +4% (Underlying) |
| Trading Profit | $987 million | $965 million | +5% (Underlying) |
| Operating Profit | $810 million | $846 million | -4% |
| Attributable Profit | $556 million | $721 million | -23% |
| Adjusted EPS | 76.9p | 74.8p | +3% |
| Basic EPS | 61.7p | 80.4p | -23% |
| Trading Cash Flow | $877 million | $999 million | -12% |
| Net Debt | $253 million | $288 million | -12% |
| Dividends per Share | 27.4p | 26.1p | +5% |
Material Changes vs. Prior Period
- Revenue Growth: Driven by strong performance in Emerging & International Markets (+18% underlying growth) and the Advanced Wound Management division, particularly the Healthpoint Biotherapeutics acquisition (revenue up 47% underlying). This offset declines in the Advanced Surgical Devices division due to weak European markets and metal-on-metal hip headwinds.
- Profitability: While Trading Profit grew 5% underlying, Operating Profit declined 4% due to increased amortization of acquisition intangibles ($88m vs $43m in 2012), restructuring costs ($58m), and acquisition-related costs ($31m). The US medical device excise tax cost approximately $24 million.
- Acquisitions: Completed acquisitions in Turkey, Brazil, and India totaling $126 million to strengthen the Emerging Markets platform. The Healthpoint acquisition (completed late 2012) contributed significantly to AWM growth.
- Capital Allocation: The Company spent $226 million on a share buy-back program and returned a total of $465 million to shareholders via dividends and buy-backs, a significant increase from the prior year.
Guidance, Outlook, and Risks
- Outlook: Management expects market conditions in 2014 to mirror the second half of 2013: stable US, challenging Europe, and higher growth in Emerging Markets. They anticipate trading profit margins to exceed 2013 performance.
- Strategic Priorities: Focus remains on investing in Emerging Markets, accelerating innovation (R&D investment increased to 5.3% of revenue), and simplifying the operating model to drive efficiency.
- Major Acquisition: Announced an agreement to acquire ArthroCare Corp. for approximately $1.7 billion, expected to close in mid-2014. This will significantly strengthen the Sports Medicine portfolio.
- Risks:
- Regulatory & Compliance: Ongoing scrutiny of healthcare industry practices; the Company is subject to a three-year settlement agreement with the SEC and DOJ regarding FCPA violations (monitorship terminated in late 2013).
- Product Liability: Exposure to claims regarding metal-on-metal hip implants and macrotextured knee components.
- Market Conditions: Economic pressure in Europe affecting elective surgery volumes and pricing pressures globally.
Key Facts for Investor Verification
- ArthroCare Acquisition: Verify the closing timeline, financing details (new $1.4 billion term loan), and integration plans for the $1.7 billion ArthroCare deal announced in February 2014.
- Emerging Markets Growth: Confirm the sustainability of the 18% underlying revenue growth in Emerging & International Markets, which now represents 13% of total revenue.
- Non-GAAP Reconciliations: Review the reconciliation of Operating Profit to Trading Profit ($810m vs $987m) to understand the impact of amortization and restructuring costs on reported earnings.
- Share Buy-back Suspension: Note that the $300 million share buy-back program was suspended following the ArthroCare announcement; verify the remaining capital allocation strategy.
- Legal Provisions: Monitor the status of provisions related to macrotextured knee revisions ($16m provision) and metal-on-metal hip claims (approx. 650 claims notified).